Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease	Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy	Recruiting	Phase 2	2026-09-21		NCT07005180

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hillhurst Biopharmaceuticals, Inc.	1
Massachusetts General Hospital (PI: Michael Schwarzschild MD,PhD, Co-PI: Stephen Gomperts MD,PhD)	1
Michael J. Fox Foundation for Parkinson's Research	32
The Parkinson Study Group	4

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Inland Northwest Research	Spokane	United States	12
Massachusetts General Hospital	Boston	United States	1015
Michigan State University	East Lansing	United States	47
Quest Research Institute	Farmington Hills	United States	47
The Parkinson's & Movement Disorder Institute	Fountain Valley	United States	2
University of Florida	Gainesville	United States	70
University of Michigan	Ann Arbor	United States	18
Weill Cornell Medical College	New York	United States	35